Contralateral pleural recurrence of adrenocortical carcinoma after surgical resection

Abstract

HHT can be used as salvage treatment for CML patients who acquire the T315I BCR-ABL mutation. 7 Chemotherapy consisting of daunorubicin, HHT and cytosine arabinoside induced CR in this patient, we added imatinib mesylate afterwards. This combination of drugs maintained complete hematological and cytogenetic remission for 31 months; and no severe side effects was observed in this case.In further studies, the effects of combination use of imatinib mesylate and HHT should be investigated to improve treatment results of Ph(+) AML. Our patient achieved molecular remission shortly after imatinib mesylate plus HHT-based antitumor chemotherapy and has long-term remission on maintenance therapy with imatinib, sustained for at least 31 months. To the best of our knowledge this is the longest reported survival of a child with de novo BCR-ABL-positive AML. Our results suggest that imatinib mesylate combined with HHT-based chemotherapy is very useful for treating childhood Ph(+) AML.Key words adrenocortical carcinoma, familial cancer, functional tumor, mitotane, pleural recurrence.Adrenocortical carcinoma (ACC) in children is rare and constitutes about 0.2% of childhood cancers. There is a strong relationship between ACC and some hereditary cancers, especially Li-Fraumeni syndrome. Most cases of ACC are endocrinologically active tumors, and include hormonal symptoms such as Correspondence: Eisuke Inage, MD,